The value of regulatory interactions developing a new modality in gene therapy- presentation at ISCT Paris May 31 - June 3

Margareth Jorvid, Head of Regulatory affairs will present a poster - The Value of early Regulatory Interactions with Authorities for emilimogene sigulatibac (INN) - a new modality in gene therapy - where and how key events in the development of ILP!00-Topical and ILP100-Oral are highlighted and their importance for derisking and accelerating the development. 

International Society for Cell- and Gene Therapies hosts a conference in Paris May 31-June 3rd. , Link to conference: https://www.isctglobal.org/isct2023/program


Abstract and poster will be published after the conference.